Stock Analysis
- United States
- /
- Life Sciences
- /
- NYSE:AVTR
Avantor First Quarter 2024 Earnings: GAAP EPS Misses Expectations
Avantor ( NYSE:AVTR ) First Quarter 2024 Results
Key Financial Results
- Revenue: US$1.68b (down 5.6% from 1Q 2023).
- Net income: US$60.4m (down 50% from 1Q 2023).
- Profit margin: 3.6% (down from 6.8% in 1Q 2023).
- GAAP EPS: US$0.089 (down from US$0.18 in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Avantor EPS Misses Expectations, Normalized Earnings Beat Expectations
Revenue was in line with analyst estimates. GAAP Earnings per share (EPS) missed analyst estimates by 34%. Normalized EPS beat analyst estimates by 10%.
Looking ahead, revenue is forecast to grow 4.2% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Life Sciences industry in the US.
Performance of the American Life Sciences industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
You still need to take note of risks, for example - Avantor has 3 warning signs (and 1 which doesn't sit too well with us) we think you should know about.
Valuation is complex, but we're helping make it simple.
Find out whether Avantor is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NYSE:AVTR
Avantor
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.
Moderate growth potential and slightly overvalued.